Skip to main content
Top
Published in: BMC Immunology 1/2021

Open Access 01-12-2021 | Lymphoma | Research article

Clinical observations of bone marrow transfusion for promoting bone marrow reconstruction after chemotherapy for AIDS-related lymphoma

Authors: Yixuan Liu, Suhong Xie, Lei Li, Yanhui Si, Weiwei Zhang, Xin Liu, Lin Guo, Baochi Liu, Renquan Lu

Published in: BMC Immunology | Issue 1/2021

Login to get access

Abstract

Background

This study investigates the effect of autologous bone marrow transfusion (BMT) on the reconstruction of both bone marrow and the immune system in patients with AIDS-related lymphoma (ARL).

Methods

A total of 32 patients with ARL participated in this study. Among them, 16 participants were treated with conventional surgery and chemotherapy (control group) and the remaining 16 patients were treated with chemotherapy followed by autologous bone marrow transfusion via a mesenteric vein (8 patients, ABM-MVI group) or a peripheral vein (8 patients, ABM-PI group). Subsequently, peripheral blood and lymphocyte data subsets were detected and documented in all patients.

Results

Before chemotherapy, no significant difference in indicators was observed between three groups of ARL patients. Unexpectedly, 2 weeks after the end of 6 courses of chemotherapy, the ABM-MVI group, and the ABM-PI group yielded an increased level of CD8+T lymphocytes, white blood cells (WBC), and platelet (PLT) in peripheral blood in comparison to the control group. Notably, the number of CD4+T lymphocytes in the ABM-PI group was significantly higher than that in the other two groups. Additionally, no significant difference in haemoglobin levels was observed before and after chemotherapy in both the ABM-MVI and ABM-PI groups, while haemoglobin levels in the control group decreased significantly following chemotherapy.

Conclusions

Autologous bone marrow transfusion after chemotherapy can promote the reconstruction of both bone marrow and the immune system. There was no significant difference in bone marrow recovery and reconstruction between the mesenteric vein transfusion group and the peripheral vein transfusion group.
Appendix
Available only for authorised users
Literature
1.
go back to reference Berry SA, Fleishman JA, Moore RD, Gebo KA. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr. 2012;59(4):368–75.CrossRef Berry SA, Fleishman JA, Moore RD, Gebo KA. Trends in reasons for hospitalization in a multisite United States cohort of persons living with HIV, 2001-2008. J Acquir Immune Defic Syndr. 2012;59(4):368–75.CrossRef
2.
go back to reference Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. Aids. 2010;24(5):697–706.CrossRef Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. Aids. 2010;24(5):697–706.CrossRef
3.
go back to reference Wang CC, Kaplan LD. Clinical management of HIV-associated hematologic malignancies. Expert Rev Hematol. 2016;9(4):361–76.CrossRef Wang CC, Kaplan LD. Clinical management of HIV-associated hematologic malignancies. Expert Rev Hematol. 2016;9(4):361–76.CrossRef
4.
go back to reference Joint United Nations Programme on HIV/AIDS (UNAIDS) and Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Update 2016. Geneva; 2009. Joint United Nations Programme on HIV/AIDS (UNAIDS) and Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS Update 2016. Geneva; 2009.
5.
go back to reference WHO. Global health sector response to HIV, 2000–2015: focus on innovations in Africa. Geneva: World Health Organisation; 2015. WHO. Global health sector response to HIV, 2000–2015: focus on innovations in Africa. Geneva: World Health Organisation; 2015.
6.
go back to reference Apostolova N, Blas-García A, Esplugues JV. Mitochondrial toxicity in HAART: an overview of in vitro evidence. Curr Pharm Des. 2011;17:2130–44.CrossRef Apostolova N, Blas-García A, Esplugues JV. Mitochondrial toxicity in HAART: an overview of in vitro evidence. Curr Pharm Des. 2011;17:2130–44.CrossRef
7.
go back to reference Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an eastern cooperative oncology group trial (E1494). J Clin Oncol. 2004;22(8):1491–500.CrossRef Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an eastern cooperative oncology group trial (E1494). J Clin Oncol. 2004;22(8):1491–500.CrossRef
8.
go back to reference Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–55.CrossRef Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141–55.CrossRef
9.
go back to reference Liu B, Chen X, Wang Y, Shi Y. Curative effect of hepatic portal venous administration of autologous bone marrow in AIDS patients with decompensated liver cirrhosis. Cell Death Dis. 2013;4:e739.CrossRef Liu B, Chen X, Wang Y, Shi Y. Curative effect of hepatic portal venous administration of autologous bone marrow in AIDS patients with decompensated liver cirrhosis. Cell Death Dis. 2013;4:e739.CrossRef
10.
go back to reference Kitchen SG, Zack JA. Stem cell-based approaches to treating HIV infection. Curr Opin HIV AIDS. 2011;6(1):68–73.CrossRef Kitchen SG, Zack JA. Stem cell-based approaches to treating HIV infection. Curr Opin HIV AIDS. 2011;6(1):68–73.CrossRef
11.
go back to reference Brunnberg U, Hentrich M, Hoffmann C, Wolf T, Hubel K. HIV-associated malignant lymphoma. Oncol Res Treat. 2017;40(3):82–7.CrossRef Brunnberg U, Hentrich M, Hoffmann C, Wolf T, Hubel K. HIV-associated malignant lymphoma. Oncol Res Treat. 2017;40(3):82–7.CrossRef
12.
go back to reference Little RF. Cancer clinical trials in persons with HIV infection. Curr Opin HIV AIDS. 2017;12(1):84–8.CrossRef Little RF. Cancer clinical trials in persons with HIV infection. Curr Opin HIV AIDS. 2017;12(1):84–8.CrossRef
13.
go back to reference Viard JPBM, Hubert JB, Aaron L. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS. 2004;18(1):45–9.CrossRef Viard JPBM, Hubert JB, Aaron L. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS. 2004;18(1):45–9.CrossRef
14.
go back to reference Hauner K, Maisch P, Retz M. Side effects of chemotherapy. Urologe A. 2017;56(4):472–9.CrossRef Hauner K, Maisch P, Retz M. Side effects of chemotherapy. Urologe A. 2017;56(4):472–9.CrossRef
15.
go back to reference Benicchi TGC, Cattaneo C, Casari S. T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation. 2005;80(5):673–82.CrossRef Benicchi TGC, Cattaneo C, Casari S. T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation. 2005;80(5):673–82.CrossRef
16.
go back to reference Schommers P, Gillor D, Hentrich M, Wyen C, Wolf T, Oette M, et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018;103(5):857–64.CrossRef Schommers P, Gillor D, Hentrich M, Wyen C, Wolf T, Oette M, et al. Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. Haematologica. 2018;103(5):857–64.CrossRef
17.
go back to reference Michieli M, Mazzucato M, Tirelli U, De Paoli P. Stem cell transplantation for lymphoma patients with HIV infection. Cell Transplant. 2011;20(3):351–70.CrossRef Michieli M, Mazzucato M, Tirelli U, De Paoli P. Stem cell transplantation for lymphoma patients with HIV infection. Cell Transplant. 2011;20(3):351–70.CrossRef
18.
go back to reference Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.CrossRef Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.CrossRef
Metadata
Title
Clinical observations of bone marrow transfusion for promoting bone marrow reconstruction after chemotherapy for AIDS-related lymphoma
Authors
Yixuan Liu
Suhong Xie
Lei Li
Yanhui Si
Weiwei Zhang
Xin Liu
Lin Guo
Baochi Liu
Renquan Lu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2021
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/s12865-021-00399-8

Other articles of this Issue 1/2021

BMC Immunology 1/2021 Go to the issue